AR057104A1 - Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica - Google Patents

Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica

Info

Publication number
AR057104A1
AR057104A1 ARP060103783A ARP060103783A AR057104A1 AR 057104 A1 AR057104 A1 AR 057104A1 AR P060103783 A ARP060103783 A AR P060103783A AR P060103783 A ARP060103783 A AR P060103783A AR 057104 A1 AR057104 A1 AR 057104A1
Authority
AR
Argentina
Prior art keywords
hydrogen
alkoxyalkyl
hydroxyalkyl
rent
heteroaryl
Prior art date
Application number
ARP060103783A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057104A1 publication Critical patent/AR057104A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuesto de diaminaspirimidinas utiles para tratar enfermedades mediadas por un antagonista de receptor de P2X3 y/o de P2X2/3, enfermedades genitourinarias, gastrointestinales, respiratorios y las relacionadas con el dolor. Reivindicacion 1: Un compuesto de la formula (I) o las sales farmacéuticamente aceptables del mismo, en la que X es -CH2-; -O-; -S(O)n- o -NRc-, en los que n es un numero de 0 a 2 y Rc es hidrogeno o alquilo; D es un oxígeno opcional; R1 es alquilo; alquenilo, cicloalquilo; cicloalquenilo; halogeno; haloalquilo o hidroxialquilo; R2, R3 y R4 con independencia entre sí son hidrogeno; alquilo; alquenilo; amino; halogeno; amido; haloalquilo; alcoxi; hidroxi; haloalcoxi; nitro; amino; hidroxialquilo; alcoxialquilo; hidroxialcoxi; alquinilalcoxi; alquilsulfonilo; arilsulfonilo; ciano; arilo; heteroarilo; heterociclilo; heterociclilalcoxi; ariloxi; heteroariloxi; aralquiloxi; heteroaralquiloxi; fenoxi opcionalmente sustituido; -C=C-Ra; -(CH2)m- (Z)n-(CO)-Rb; -(CH)2)m-(Z)n-SO2-(NRc)n-Rb, en los que m y n con independencia entre sí son 0 o 1, Z es O o NRc, Ra es hidrogeno; alquilo; arilo; aralquilo; heteroarilo; heteroaralquilo; hidroxialquilo; alcoxialquilo; alquilsulfonilalquilo; aminoalquilo; cianoalquilo; alquilsililo, cicloalquilo, cicloalquilalquilo; heterociclilo; y heterociclilalquilo; Rb es hidrogeno, alquilo, hidroxi, alcoxi, amino, hidroxialquilo o alcoxialquilo y cada Rc con independencia es hidrogeno o alquilo; o R2 y R3 junto con los átomos a los que están unidos pueden formar un anillo de cinco o seis eslabones que incluye opcionalmente uno o dos heteroátomos elegidos entre O, S y N; R5 es hidrogeno; alquilo; arilo; aralquilo; heteroarilo; heteroaralquilo; hidroxialquilo; alcoxialquilo; alquilsulfonilalquilo; aminoalquilo; cianoalquilo; alquilsililo, cicloalquilo, cicloalquilalquilo; heterociclo; o heterociclilalquilo; R6 es hidrogeno; alquilo; halogeno; haloalquilo; amino; o alcoxi; y R7 y R8 con independencia entre sí son hidrogeno; alquilo; alcoxialquilo; aminoalquilo; aminosulfonilo; cicloalquilo; cicloalquilalquilo; haloalquilo; haloalcoxi; hidroxialquilo; alcoxialquilo; alquilsulfonilo; alquilsulfoilalquilo; aminocarboniloxialquilo; hidroxicarbonilalquilo; hidroxialquiloxicarbonilalquilo; arilo; aralquilo; arilsulfonilo; heteroarilo; heteroarilo; heteroarilalquilo; heteroarilsulfonilo; heterociclilo; o heterociclilalquilo.
ARP060103783A 2005-09-01 2006-08-30 Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica AR057104A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71339905P 2005-09-01 2005-09-01

Publications (1)

Publication Number Publication Date
AR057104A1 true AR057104A1 (es) 2007-11-14

Family

ID=37149621

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103783A AR057104A1 (es) 2005-09-01 2006-08-30 Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica

Country Status (9)

Country Link
US (1) US7531547B2 (es)
EP (1) EP1924564B1 (es)
JP (1) JP4850911B2 (es)
CN (1) CN101296907B (es)
AR (1) AR057104A1 (es)
CA (1) CA2619919C (es)
ES (1) ES2612890T3 (es)
TW (1) TW200740773A (es)
WO (1) WO2007025899A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1924264T5 (en) * 2005-09-01 2014-03-24 Hoffmann La Roche Diaminopyrimidines as P2X3- and P2X2 / 3 modulators
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
CN101679246A (zh) 2007-03-30 2010-03-24 盐野义制药株式会社 新型吡咯啉酮衍生物以及包含其的药物组合物
CA2715835C (en) 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
TW201016702A (en) * 2008-09-25 2010-05-01 Shionogi & Co Novel pyrrolinone derivative and pharmaceutical composition comprising the same
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
RU2565073C2 (ru) 2010-08-10 2015-10-20 Сионоги Энд Ко., Лтд. Триазиновое производное и включающая его фармацевтическая композиция, обладающая анальгетической активностью
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
RS57758B1 (sr) 2011-04-08 2018-12-31 Janssen Sciences Ireland Uc Pirimidinski derivati za tretman viralnih infekcija
IN2014MN00862A (es) 2011-11-09 2015-04-17 Janssen R & D Ireland
JP6124351B2 (ja) 2012-02-09 2017-05-10 塩野義製薬株式会社 複素環および炭素環誘導体
LT2872515T (lt) 2012-07-13 2016-10-10 Janssen Sciences Ireland Uc Makrocikliniai purinai, skirti virusinių infekcijų gydymui
EP2712866A1 (en) * 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
NZ705589A (en) 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US9663474B2 (en) 2012-11-16 2017-05-30 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US9598378B2 (en) 2013-02-21 2017-03-21 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
CN105377833B (zh) 2013-05-24 2018-11-06 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的吡啶酮衍生物
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
MX361527B (es) 2013-06-27 2018-12-07 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
JP6401788B2 (ja) 2013-07-30 2018-10-10 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
KR102196885B1 (ko) 2013-08-23 2020-12-30 애퍼런트 파마슈티컬스 인크. 급성, 아급성 또는 만성 기침의 치료를 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조절제
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
EP3164132A4 (en) 2014-07-03 2018-02-21 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
JPWO2016084922A1 (ja) * 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
DK3355889T3 (da) 2015-09-29 2023-05-15 Afferent Pharmaceuticals Inc Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste
MA43821A (fr) * 2016-03-14 2018-11-28 Afferent Pharmaceuticals Inc Pyrimidines et variantes de celles-ci, et leurs utilisations
US10662162B2 (en) 2016-03-25 2020-05-26 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
CA3027471A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
EA038646B1 (ru) 2016-09-29 2021-09-28 Янссен Сайенсиз Айрлэнд Анлимитед Компани Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
RU2650780C1 (ru) 2016-12-06 2018-04-17 Общество с ограниченной ответственностью "Анальгетики будущего" Пептидный модулятор пуринергических рецепторов
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CA3132731A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
US20220204475A1 (en) * 2019-04-30 2022-06-30 Beijing Tide Pharmaceutical Co., Ltd. Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
US3849470A (en) * 1969-03-06 1974-11-19 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore,and method
US3991050A (en) * 1969-03-06 1976-11-09 Burroughs Wellcome Co. Preparation of β-Amino-α-benzylacrylonitriles
US3850927A (en) * 1969-03-06 1974-11-26 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore,and method
US3855265A (en) * 1969-03-06 1974-12-17 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore, and method
US4052553A (en) * 1969-03-06 1977-10-04 Burroughs Wellcome Co. 5-benzyl pyrimidines intermediates therefore, and method
US3852276A (en) * 1969-03-06 1974-12-03 Burroughs Wellcome Co 5-benzyl pyrimidines intermediate therefore, and method
CH513181A (de) * 1969-06-12 1971-09-30 Hoffmann La Roche Verfahren zur Herstellung von N-Oxyden von Benzylpyrimidinen
US4143227A (en) * 1973-02-26 1979-03-06 Hoffmann-La Roche Inc. Process for substituted 5-benzyl-2,4-diamino-pyrimidines
US4255574A (en) * 1973-02-26 1981-03-10 Hoffmann-La Roche Inc. Process for preparing 2,4-diamino-pyrimidines
US3931181A (en) * 1973-07-27 1976-01-06 Hoffmann-La Roche Inc. 2,4-Diamino-5-benzylpyrimidines
US4515948A (en) * 1973-09-12 1985-05-07 Hoffmann-La Roche Inc. 2,4-Diamino-5-(4-amino and 4-dimethylamino-3,5-dimethoxy benzyl)pyrimidines
CH591457A5 (es) * 1973-11-08 1977-09-15 Hoffmann La Roche
US3940393A (en) * 1974-06-21 1976-02-24 American Home Products Corporation Synthesis of 2,6-diaminopyrimidines
US4039543A (en) * 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
US4033962A (en) * 1975-06-26 1977-07-05 Hoffman-La Roche Inc. 2,4-Diamino-pyrimidine derivatives and processes
GB1582245A (en) * 1976-06-09 1981-01-07 Wellcome Found Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives
US4115650A (en) * 1976-11-17 1978-09-19 Hoffmann-La Roche Inc. Process for preparing 2,4-diamino-5-(substituted benzyl)-pyrimidines
US4075209A (en) * 1977-02-07 1978-02-21 Hoffmann-La Roche, Inc. Process for preparing substituted 2,4-diaminopyrimidines and isoxazole intermediate
FR2397407A2 (fr) * 1977-07-11 1979-02-09 Dick Pierre Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides
US4258045A (en) * 1979-11-30 1981-03-24 Merck & Co., Inc. Inhibitor of dihydrofolate reductase
DE3045720A1 (de) * 1980-12-04 1982-07-08 Basf Ag, 6700 Ludwigshafen N-pyrimidinyl-carbaminsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FR2502152A1 (fr) * 1981-03-20 1982-09-24 Panmedica Laboratoires Nouveaux derives solubles n2 substitues de la diamino-2,4-benzyl-5-pyrimidines, leur procede de preparation et medicaments les contenant
IT1138146B (it) * 1981-08-11 1986-09-17 Proter Spa Processo per la produzione della 2,4-diammino-(3,5-dimetossi-4-metos sietossi-benzil)-pirimidina
US4590271A (en) * 1982-05-01 1986-05-20 Burroughs Wellcome Co. 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials
US4587341A (en) * 1982-05-07 1986-05-06 Burroughs Wellcome Co. 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
FR2595697B1 (fr) 1986-03-13 1988-07-08 Rousselot Cie Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant
HU199683B (en) * 1987-07-22 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions analgesic, antiphlogistic, antipyretic, antianginic and/or antioxidative activity
US4996198A (en) * 1988-07-11 1991-02-26 Hoffmann-La Roche Inc. Anticoccidial composition
US5240640A (en) * 1990-06-04 1993-08-31 Coulter Corporation In situ use of gelatin or an aminodextran in the preparation of uniform ferrite particles
US5258373A (en) * 1991-07-17 1993-11-02 Hoffmann-La Roche Inc. Anticoccidial compositions
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
NZ296532A (en) * 1994-11-24 2000-02-28 F Substituted 5-benzyl-2,4,-diaminopyrimidines
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6583148B1 (en) * 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6211185B1 (en) * 1999-05-05 2001-04-03 Veterinary Pharmacy Corporation Concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution, and a suspending agent
ATE380180T1 (de) 1999-09-03 2007-12-15 Actelion Pharmaceuticals Ltd Bis-sulfonamiden
JP4919566B2 (ja) 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
AU2001263850A1 (en) 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en) 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
KR100835770B1 (ko) 2000-09-25 2008-06-09 액테리온 파마슈티칼 리미티드 엔도텔린 길항 활성을 갖는 아릴알칸-설폰아마이드
NZ525614A (en) * 2000-12-18 2005-03-24 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
WO2002083650A1 (en) 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
JP2005508288A (ja) 2001-05-18 2005-03-31 アボット・ラボラトリーズ Ｐ２ｘ３およびｐ２ｘ２／３含有受容体を阻害するトリ置換−ｎ−［（１ｓ）−１，２，３，４−テトラヒドロ−１−ナフタレニル］ベンズアミド類
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
KR100822530B1 (ko) * 2004-03-05 2008-04-16 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 길항물질로서의 다이아미노피리미딘

Also Published As

Publication number Publication date
CN101296907B (zh) 2013-03-27
JP4850911B2 (ja) 2012-01-11
ES2612890T3 (es) 2017-05-19
US7531547B2 (en) 2009-05-12
JP2009513565A (ja) 2009-04-02
CA2619919A1 (en) 2007-03-08
CN101296907A (zh) 2008-10-29
TW200740773A (en) 2007-11-01
EP1924564A1 (en) 2008-05-28
CA2619919C (en) 2014-04-01
EP1924564B1 (en) 2016-11-09
WO2007025899A1 (en) 2007-03-08
US20070049758A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
AR057104A1 (es) Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica
AR055618A1 (es) Diaminopirimidinas como moduladores de p2x3 y p2x2/3, composiciones farmaceuticas que las comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades relacionadas.
AR048302A1 (es) DERIVADOS DE PIRAZOLO-PIRIMIDINA, DE PIRAZOLO-PIRIMIDINONA, DE PIRAZOLO-PIRIDINA Y DE PIRAZOLO-PIRAZINA FUSIONADOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA PREPARACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA CINASA P38
AR049652A1 (es) Sales cuaternarias antagonistas del receptor ccr2
AR050208A1 (es) Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
ECSP066671A (es) Nuevos derivados de quinolina
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
PE20060273A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3
AR057769A1 (es) Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas
CY1109015T1 (el) Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα
CY1113450T1 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
AR049126A1 (es) Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
AR077143A1 (es) Compuestos insecticidas
AR038249A1 (es) Compuestos derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos derivados en la preparacion de un medicamento
AR048834A1 (es) Compuestos derivados de piperidina o tropano; metodos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por quimioquinas (ccr5)
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR074817A1 (es) Dihidropiridona-amidas como moduladores de p2x7
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α

Legal Events

Date Code Title Description
FA Abandonment or withdrawal